-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|July 16, 2024

Navigating Biosimilar Uptake in New Patients

The panel discuss if including biosimilars on formulary at parity is enough to support their adoption.

Episodes in this series

EP. 1 Biologics Utilization Impacting US Health Care Spending

EP. 1 Biologics Utilization Impacting US Health Care Spending

EP. 2 Current Landscape of Biosimilar Use in US Healthcare Space

EP. 2 Current Landscape of Biosimilar Use in US Healthcare Space

EP. 3 Interchangeability Impacting Biosimilar Uptake

EP. 3 Interchangeability Impacting Biosimilar Uptake

EP. 4 The Impact of Payer Coverage and Reimbursement on Biosimilars

EP. 4 The Impact of Payer Coverage and Reimbursement on Biosimilars

EP. 5 Navigating Biosimilar Uptake in New Patients

EP. 5 Navigating Biosimilar Uptake in New Patients

EP. 6 Economic Impacts and Pricing Strategies Surrounding Biosimilars

EP. 6 Economic Impacts and Pricing Strategies Surrounding Biosimilars

A panel of 4 experts on biosimilars

EP. 7 Private Label Biosimilars

EP. 8 Biosimilars in the Commercial Sector

EP. 8 Biosimilars in the Commercial Sector

EP. 9 The Influence of Employer Preferences And Adoption of Biosimilars

EP. 9 The Influence of Employer Preferences And Adoption of Biosimilars

EP. 10 Out of Pocket Costs Associated with Biosimilar Use

EP. 10 Out of Pocket Costs Associated with Biosimilar Use

EP. 11 Unmet Needs and Future Initiatives

EP. 11 Unmet Needs and Future Initiatives

EP. 12 Ideal Goals for Biosimilar Utilization

EP. 12 Ideal Goals for Biosimilar Utilization

EP. 13 Foreseeable Biosimilar Trends

EP. 13 Foreseeable Biosimilar Trends

EP. 14 Legislative Support for Biosimilars

EP. 14 Legislative Support for Biosimilars

EP. 15 Key Takeaways for Biosimilar Utilization

EP. 15 Key Takeaways for Biosimilar Utilization

Video content above is prompted by the following:

How do you direct new-start patients to a biosimilar? What about switching?
Payers require generic medications over brand name in most instances. Why isn’t this the case for biosimilars?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Experts featured in this series.

The Right Fit First: How Psychiatrists Approach Initial Treatment and Patient Adherence

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 23rd 2026 | Updated: June 16th 2026

Experts featured in this series.

Formulary Frustrations: How Insurance Constraints Shape Psychiatric Treatment Decisions

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 23rd 2026 | Updated: June 16th 2026

Navigating the Human Side of Extrapulmonary Neuroendocrine Carcinoma: Patient Burden and Caregiver Support

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

June 22nd 2026

The 5-Year Horizon: Evolving Paradigms in Ischemic Stroke Management

ByMark Makhinson, PharmD, MBA,Andrew Russman, DO, FAHA, FAAN,Danison Emmerson, MD,David Z. Rose, MD

June 22nd 2026

Closing the Gap: Underrecognition and the Critical Need for Early Diagnosis in Extrapulmonary Neuroendocrine Carcinoma

ByRyan Haumschild, PharmD, MBA,William K. Oh, MD,Aman Chauhan, MD,Namrata Vijayvergia, MD,Sandy Kotiah, MD

June 22nd 2026

Trending on AJMC

CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes

FDA Approves Palbociclib for HR+, HER2+ Breast Cancer Maintenance

Respiratory Biologics Linked to Reduced Asthma Exacerbations Across Patient Groups

Zanubrutinib Tops Rivals in Real-World CLL Survival Study

SGLT2 Inhibitors Tied to Lower Platelet Activation in HFrEF